Zhang Qiao, Xu Xiaomeng, Jiang Dongxian, Wang Yunzhi, Wang Haixing, Zhu Jiajun, Tang Shaoshuai, Wang Ronghua, Zhao Shuang, Li Kai, Feng Jinwen, Xiang Hang, Yao Zhenmei, Xu Ning, Fang Rundong, Guo Wenjia, Liu Yu, Hou Yingyong, Ding Chen
Center for Cell and Gene Therapy, Clinical Research Center for Cell-based Immunotherapy, Shanghai Pudong Hospital, State Key Laboratory of Genetic Engineering, School of Life Sciences, Human Phenome Institute, Fudan University, Shanghai, 200433, China.
Department of Pathology, Zhongshan Hospital Fudan University, Shanghai, China.
Cell Discov. 2025 Jan 7;11(1):2. doi: 10.1038/s41421-024-00742-4.
Ampullary adenocarcinoma (AMPAC) is a rare and heterogeneous malignancy. Here we performed a comprehensive proteogenomic analysis of 198 samples from Chinese AMPAC patients and duodenum patients. Genomic data illustrate that 4q loss causes fatty acid accumulation and cell proliferation. Proteomic analysis has revealed three distinct clusters (C-FAM, C-AD, C-CC), among which the most aggressive cluster, C-AD, is associated with the poorest prognosis and is characterized by focal adhesion. Immune clustering identifies three immune clusters and reveals that immune cluster M1 (macrophage infiltration cluster) and M3 (DC cell infiltration cluster), which exhibit a higher immune score compared to cluster M2 (CD4 T-cell infiltration cluster), are associated with a poor prognosis due to the potential secretion of IL-6 by tumor cells and its consequential influence. This study provides a comprehensive proteogenomic analysis for seeking for better understanding and potential treatment of AMPAC.
Cell Discov. 2025-1-7
J Hematol Oncol. 2022-11-25
Recent Pat Anticancer Drug Discov. 2024
Front Mol Biosci. 2022-8-26
Cell Rep Med. 2024-1-16
Nat Commun. 2024-11-22
Natl Sci Rev. 2025-7-14
Cell Chem Biol. 2023-10-19
J Natl Compr Canc Netw. 2023-7
Phenomics. 2023-1-5
DNA Cell Biol. 2022-12
J Hematol Oncol. 2022-11-25
Front Oncol. 2022-5-4
Zotero 插件